The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Implementing MRD-guided treatment in community myeloma care
Jesús San-Miguel, MD, PhD, University of Navarra, Pamplona, Spain, discusses the practical requirements for implementing measurable residual disease (MRD)-guided treatment in multiple myeloma. Dr San-Miguel highlights the affordability and accessibility of standardized EuroFlow testing and its potential to guide treatment intensification and early intervention in routine clinical practice. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
